Aptevo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Aptevo Therapeutics Inc reported a quarterly adjusted loss of $1.86 per share for the quarter ended September 30, an improvement from last year's loss of $355.20 per share. The company reported zero revenue and a total loss of $9.03 million. Despite a 1.4% rise in shares this quarter, they have lost 98.3% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $420.00, significantly above the last closing price of $1.47.